Dyslipidemia, Diabetes, And Cardiovascular Risk: Clinical Strategies and Evolving Treatment

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe key treatment recommendations in accordance with current guidelines and recommendations from major expert groups, and how they would apply to type 2 diabetes treatment design that optimizes cardiovascular risk reduction
Initiate and advance treatments for diabetes and dyslipidemia using newer pharmacotherapies with evidence-based benefits in blunting cardiovascular risk, including GLP-1 receptor agonists, SGLT2 inhibitors, icosapent ethyl, and PCSK9 inhibitors
Overcome clinical barriers to the timely and effective therapeutic initiation of the latest antidiabetes and dyslipidemia lipid treatments that have demonstrated cardiovascular benefits
Target Audience

Primary care providers, doctors of osteopathic medicine, diabetes specialists (such as endocrinologists and diabetologists), cardiologists, lipidologists, nurse practitioners, physician assistants and pharmacists. Other medical professionals, such certified diabetes educators, may also benefit from the education.